Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kura Oncology : Corporate Presentation - September 2021

09/13/2021 | 12:22pm EST

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

Corporate Presentation - September 2021

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib, KO-539 and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investment Highlights

Targeted Oncology

Proprietary Pipeline

Advancing targeted oncology drug candidates using a precision medicine approach; fast-to-market strategy; global commercial rights

KO-539

  • Novel menin inhibitor with potential to target 35% or more of AML
  • Encouraging safety, tolerability and clinical activity in multiple genetically defined subgroups of AML
  • Genetically enriched Phase 1b expansion cohorts now enrolling
    Tipifarnib

• Breakthrough Therapy* and Fast Track Designations from FDA

• Registration-directed trial in HRAS mutant HNSCC ongoing

• Clinical collaboration to evaluate tipifarnib + PI3Kα inhibitor alpelisib in HNSCC

Next-Generation Farnesyl Transferase Inhibitor

• KO-2806 nominated as development candidate for IND-enabling studies

Strong

$567.5 million in cash** provides runway into 2024

Financials

* For the treatment of patients with recurrent or metastatic HRAS mutant HNSCC with

3

variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy

** Cash, cash equivalents and short-term investments as of June 30, 2021

Kura Leadership Team and Board of Directors

Proven oncology drug development and commercialization expertise

Leadership Team

Troy Wilson, Ph.D., J.D.

President & Chief Executive Officer

Stephen Dale, M.D.

Chief Medical Officer

Kirsten Flowers

Chief Commercial Officer

Kathleen Ford

Chief Operating Officer

Marc Grasso, M.D.

Chief Financial Officer & Chief Business Officer

Board of Directors

Troy Wilson, Ph.D., J.D. (Chairman)

President and CEO, Kura Oncology

Faheem Hasnain (Lead Director)

Chairman and Chief Executive Officer, Gossamer Bio

Helen Collins, M.D.

Former Chief Medical Officer, Five Prime Therapeutics

Thomas Malley

President, Mossrock Capital

Diane Parks

Former Head of U.S. Commercial, Kite Pharma

Carol Schafer

Former Vice Chair, Equity Capital Markets, Wells Fargo

Steven Stein, M.D.

Chief Medical Officer, Incyte

Mary Szela

President and CEO, TriSalus Life Sciences

4

Drug Candidate Pipeline

Program

Preclinical

Phase 1

Phase 2

Registration

Directed

KO-539

Acute Myeloid Leukemia (AML)

KOMET-001 Trial

Menin Inhibitor

Enrollment of Phase 1b expansion cohorts ongoing

HRAS mutant Head & Neck Squamous Cell Carcinoma (HNSCC)

AIM-HN Trial

Tipifarnib

Enrollment in registration-directed trial ongoing

Farnesyl Transferase

HRAS / PIK3CA*

Inhibitor

Dependent HNSCC

KURRENT Trial

Initiation of PI3Kα inhibitor combination study expected in Q4 2021

KO-2806

Solid Tumors

Next-Generation

Farnesyl Transferase

IND-enabling studies ongoing

Inhibitor

* Initial cohort will be in PIK3CA-dependent HNSCC patients

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Kura Oncology Inc. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 16:21:05 UTC.


© Publicnow 2021
All news about KURA ONCOLOGY, INC.
11/26Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Ra..
MT
11/24Health Care Stocks Unable to Return to Positive Ground By Wednesday Close
MT
11/24Kura Oncology Shares Sink After FDA Imposes Partial Hold on Phase 1b Study of KO-539
MT
11/24Health Care Stocks Marginally Lower After Paring Losses
MT
11/24HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rati..
MT
11/24Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical..
MT
11/24Wall Street Set to Open in Red Territory; US GDP Growth Upwardly Revised in Q3
MT
11/24Health Care Stocks Mixed Premarket Wednesday
MT
11/24Health Care
MT
11/24Top Premarket Decliners
MT
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -134 M - -
Net cash 2021 497 M - -
P/E ratio 2021 -6,11x
Yield 2021 -
Capitalization 825 M 825 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 116
Free-Float 94,3%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 12,39 $
Average target price 36,71 $
Spread / Average Target 196%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-62.06%825
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819